Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
David Kukis
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Procedures
Chemicals & Drugs
Living Beings
Concepts & Ideas
Disorders
Sign-in to see full Profile
Network (preview)
35
DeNardo, Sally
33
DeNardo, Gerald
22
Meares, Claude
22
O'Donnell, Robert
20
Shen, Sui
14
Miers, Laird
14
Kroger, Linda
12
Lamborn, Kathleen
10
Goldstein, Desiree
10
Yuan, Aina
8
Mirick, Gary
7
Richman, Carol
7
Salako, QA
4
Srivastava, Suresh
4
Denardo, DA
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of David Kukis (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Hausner Sven H; Kukis David L; Gagnon M Karen J; Stanecki Catherine E; Ferdani Riccardo; Marshall John F; Anderson Carolyn J; Sutcliffe Julie L
Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.
Molecular imaging : official journal of the Society for Molecular Imaging 2009;8(2):111-21.
-
2009: Martin Shiloh M; O'Donnell Robert T; Kukis David L; Abbey Craig K; McKnight Hayes; Sutcliffe Julie L; Tuscano Joseph M
Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2009;11(2):79-87.
-
2008: Seo Jai Woong; Zhang Hua; Kukis David L; Meares Claude F; Ferrara Katherine W
A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging.
Bioconjugate chemistry 2008;19(12):2577-84.
-
2008: Jarrett Benjamin R; Gustafsson Björn; Kukis David L; Louie Angelique Y
Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging.
Bioconjugate chemistry 2008;19(7):1496-504.
-
2005: Richman Carol M; Denardo Sally J; O'Donnell Robert T; Yuan Aina; Shen Sui; Goldstein Desiree S; Tuscano Joseph M; Wun Ted; Chew Helen K; Lara Primo N; Kukis David L; Natarajan Arutselvan; Meares Claude F; Lamborn Kathleen R; DeNardo Gerald L
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5920-7.
-
2003: DeNardo Sally J; DeNardo Gerald L; Yuan A; Richman Carol M; O'Donnell Robert T; Lara Primo N; Kukis David L; Natarajan Arutselvan; Lamborn Kathleen R; Jacobs Frederik; Siantar Christine L Hartmann
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3938S-44S.
-
2003: Tuscano Joseph M; O'Donnell Robert T; Miers Laird A; Kroger Linda A; Kukis David L; Lamborn Kathleen R; Tedder Thomas F; DeNardo Gerald L
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Blood 2003;101(9):3641-7.
-
2002: Burke Patricia A; DeNardo Sally J; Miers Laird A; Kukis David L; DeNardo Gerald L
Combined modality radioimmunotherapy. Promise and peril.
Cancer 2002;94(4 Suppl):1320-31.
-
2002: O'Donnell Robert T; DeNardo Sally J; Miers Laird A; Lamborn Kathleen R; Kukis David L; DeNardo Gerald L; Meyers Frederick J
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
The Prostate 2002;50(1):27-37.
-
2001: Kukis D L; Novak-Hofer I; DeNardo S J
Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer.
Cancer biotherapy & radiopharmaceuticals 2001;16(6):457-67.
-
2001: DeNardo G L; DeNardo S J; Kukis D L; O'Donnell R T; Shen S; Mirick G R; Meares C F
Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(9):1324-33.
-
2001: O'Donnell R T; DeNardo S J; Yuan A; Shen S; Richman C M; Lara P N; Griffith I J; Goldstein D S; Kukis D L; Martinez G S; Mirick G R; DeNardo G L; Meyers F J
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1561-8.
-
2000: DeNardo G L; DeNardo S J; Wessels B W; Kukis D L; Miyao N; Yuan A
131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
Cancer biotherapy & radiopharmaceuticals 2000;15(6):547-60.
-
2000: DeNardo G L; DeNardo S J; O'Donnell R T; Kroger L A; Kukis D L; Meares C F; Goldstein D S; Shen S
Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
Clinical lymphoma 2000;1(2):118-26.
-
2000: O'Donnell R T; Shen S; Denardo S J; Wun T; Kukis D L; Goldstein D S; Denardo G L
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
Anticancer research 2000;20(5C):3647-55.
-
2000: O'Donnell R T; DeNardo S J; DeNardo G L; Miers L; Lamborn K R; Kukis D L; Meyers F J
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
The Prostate 2000;44(3):187-92.
-
2000: DeNardo G L; O'Donnell R T; Shen S; Kroger L A; Yuan A; Meares C F; Kukis D L; DeNardo S J
Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(5):952-8.
-
1999: O'Donnell R T; DeNardo G L; Kukis D L; Lamborn K R; Shen S; Yuan A; Goldstein D S; Carr C E; Mirick G R; DeNardo S J
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(12):2014-20.
-
1999: Kukis D L; DeNardo S J; Mills S L; Shen S; O'Donnell R T; DeNardo G L
Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.
Cancer biotherapy & radiopharmaceuticals 1999;14(5):363-9.
-
1999: O'Donnell R T; DeNardo G L; Kukis D L; Lamborn K R; Shen S; Yuan A; Goldstein D S; Mirick G R; DeNardo S J
67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3330s-3336s.
-
1999: Richman C M; DeNardo S J; O'Donnell R T; Goldstein D S; Shen S; Kukis D L; Kroger L A; Yuan A; Boniface G R; Griffith I J; DeNardo G L
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3243s-3248s.
-
1999: O'Donnell R T; Leigh B R; Christensen S D; Goldstein D S; Kukis D L; Shen S; Yuan A; DeNardo D A; Kroger L A; DeNardo G L
Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
Cancer biotherapy & radiopharmaceuticals 1999;14(3):167-76.
-
1999: DeNardo G L; Kukis D L; Shen S; DeNardo D A; Meares C F; DeNardo S J
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):533-41.
-
1999: DeNardo S J; DeNardo G L; Kukis D L; Shen S; Kroger L A; DeNardo D A; Goldstein D S; Mirick G R; Salako Q; Mausner L F; Srivastava S C; Meares C F
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(2):302-10.
-
1998: Kukis D L; DeNardo S J; DeNardo G L; O'Donnell R T; Meares C F
Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(12):2105-10.
-
1998: Denardo S J; Richman C M; Kukis D L; Shen S; Lamborn K R; Miers L A; Kroger L A; Perez E A; Denardo G L
Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
Anticancer research 1998;18(6A):4011-8.
-
1998: O'Donnell R T; DeNardo S J; Miers L A; Kukis D L; Mirick G R; Kroger L A; DeNardo G L
Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
Cancer biotherapy & radiopharmaceuticals 1998;13(5):351-61.
-
1998: Denardo G L; Denardo S J; Kukis D L; O'Donnell R T; Shen S; Goldstein D S; Kroger L A; Salako Q; Denardo D A; Mirick G R; Mausner L F; Srivastava S C; Meares C F
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Anticancer research 1998;18(4B):2779-88.
-
1998: DeNardo S J; Kukis D L; Miers L A; Winthrop M D; Kroger L A; Salako Q; Shen S; Lamborn K R; Gumerlock P H; Meares C F; DeNardo G L
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(5):842-9.
-
1997: DeNardo S J; Kroger L A; Lamborn K R; Miers L A; O'Donnell R T; Kukis D L; Richman C M; DeNardo G L
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
Cancer 1997;80(12 Suppl):2583-90.
-
1997: DeNardo G L; Kukis D L; DeNardo S J; Shen S; Mausner L F; O'Donnell R T; Lamborn K R; Meyers F J; Srivastava S C; Miers L A
Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.
Cancer 1997;80(12 Suppl):2576-82.
-
1997: Denardo S J; Richman C M; Goldstein D S; Shen S; Salako Q; Kukis D L; Meares C F; Yuan A; Welborn J L; Denardo G L
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Anticancer research 1997;17(3B):1735-44.
-
1997: DeNardo S J; Kukis D L; Kroger L A; O'Donnell R T; Lamborn K R; Miers L A; DeNardo D G; Meares C F; DeNardo G L
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(8):4000-4.
-
1997: DeNardo G L; Kukis D L; Shen S; Mausner L F; Meares C F; Srivastava S C; Miers L A; DeNardo S J
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):71-9.
-
1995: Li M; Meares C F; Salako Q; Kukis D L; Zhong G R; Miers L; DeNardo S J
Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
Cancer research 1995;55(23 Suppl):5726s-5728s.
-
1995: Kukis D L; DeNardo G L; DeNardo S J; Mirick G R; Miers L A; Greiner D P; Meares C F
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
Cancer research 1995;55(4):878-84.
-
1994: Goodwin D A; Meares C F; Watanabe N; McTigue M; Chaovapong W; Ransone C M; Renn O; Greiner D P; Kukis D L; Kronenberger S I
Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
Cancer research 1994;54(22):5937-46.
-
1994: Kukis D L; Diril H; Greiner D P; DeNardo S J; DeNardo G L; Salako Q A; Meares C F
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.
Cancer 1994;73(3 Suppl):779-86.
-
1994: DeNardo G L; Kroger L A; DeNardo S J; Miers L A; Salako Q; Kukis D L; Fand I; Shen S; Renn O; Meares C F
Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
Cancer 1994;73(3 Suppl):1012-22.
-
1992: Studer M; Kroger L A; DeNardo S J; Kukis D L; Meares C F
Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo.
Bioconjugate chemistry 1992;3(5):424-9.
-
1991: DeNardo G; DeNardo S; Kukis D; Diril H; Suey C; Meares C
Strategies for enhancement of radioimmunotherapy.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(6):633-40.
-
1990: Meares C F; Moi M K; Diril H; Kukis D L; McCall M J; Deshpande S V; DeNardo S J; Snook D; Epenetos A A
Macrocyclic chelates of radiometals for diagnosis and therapy.
The British journal of cancer. Supplement 1990;10():21-6.
-
1990: Deshpande S V; DeNardo S J; Kukis D L; Moi M K; McCall M J; DeNardo G L; Meares C F
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(4):473-9.
Sign-in to see more
